This clinical trial is focused on studying a rare type of blood cancer called Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). The study will evaluate the effectiveness and safety of a combination of two treatments: tagraxofusp and venetoclax. Tagraxofusp is a medication that targets specific cells in the body, while venetoclax is a type of drug known as a BCL-2 inhibitor, which helps to kill cancer cells. The purpose of the study is to see how well these two medications work together in patients who have not received any previous treatment for BPDCN.
Participants in the study will receive both tagraxofusp and venetoclax over a period of time. Tagraxofusp is given as an infusion, which means it is delivered directly into the bloodstream through a vein, while venetoclax is taken orally as a tablet. The study will monitor how patients respond to the treatment combination, looking for signs of improvement in their condition. The trial will also assess the safety of the treatment, checking for any side effects that may occur.
The study aims to determine the rate of complete remission, which means the cancer is no longer detectable, or a significant reduction in cancer symptoms after three cycles of treatment. Researchers will also look at other outcomes, such as how long patients remain free from cancer progression and overall survival rates. This trial is an important step in finding more effective treatments for BPDCN and improving the quality of life for those affected by this rare cancer.
France 